Orthofix, Pfizer FCPA Cases A Sign Of What's To Come

Law360, New York (September 21, 2012, 1:14 PM EDT) -- In November 2009, Lanny Breuer, assistant attorney general for the U.S. Department of Justice’s Criminal Division, publicly announced that the DOJ intended to focus on U.S. Foreign Corrupt Practices Act violations in the pharmaceutical and medical device industries.[1] According to the DOJ, “The depth of government involvement in foreign health systems, combined with fierce industry competition and the closed nature of many public formularies, creates, in our view, a significant risk that corrupt payments will infect the process.”[2] 

In 2010, the then-chief of the U.S. Securities Exchange Commission’s FCPA unit reiterated the sentiment.[3] With several settlements in the past months, the...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Beta
Ask a question!